Pivotal phase 3 trial of RPL-554
Phase of Trial: Phase III
Latest Information Update: 09 Apr 2019
Price : $35 *
At a glance
- Drugs Ensifentrine (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Sponsors Verona Pharma
- 09 Apr 2019 According to a Verona Pharma media release, the company will start this study in 2020.
- 14 Aug 2018 New trial record
- 07 Aug 2018 According to a Verona Pharma media release, this trial is expected to commence later 2019.